β2-Agonist therapy may contribute to the air pollution and IL-6-associated risk of developing severe asthma with dual-positive TH2/TH17 cells

Sergio E. Chiarella; G. R.Scott Budinger; Gökhan M. Mutlu

doi:10.1016/j.jaci.2014.09.037

β₂-Agonist therapy may contribute to the air pollution and IL-6-associated risk of developing severe asthma with dual-positive T_H2/T_H17 cells

Sergio E. Chiarella, G. R.Scott Budinger, Gökhan M. Mutlu

Medicine, Pulmonary Division

Research output: Contribution to journal › Letter › peer-review

7 Scopus citations

Original language	English (US)
Pages (from-to)	290-291
Number of pages	2
Journal	Journal of Allergy and Clinical Immunology
Volume	135
Issue number	1
DOIs	https://doi.org/10.1016/j.jaci.2014.09.037
State	Published - Jan 1 2015

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1016/j.jaci.2014.09.037

Cite this

@article{7c6a71c1979e4e818d8600ddd9a36823,

title = "β2-Agonist therapy may contribute to the air pollution and IL-6-associated risk of developing severe asthma with dual-positive TH2/TH17 cells",

author = "Chiarella, {Sergio E.} and Budinger, {G. R.Scott} and Mutlu, {G{\"o}khan M.}",

note = "Funding Information: Supported by National Institutes of Health grants R01 ES015024 (to G.M.M.) and R01 ES013995 (to G.R.S.B.). Funding Information: Disclosure of potential conflict of interest: G. R. S. Budinger has received research support from the National Institutes of Health (NIH) and is Deputy Editor of the American Thoracic Society (ATS). G. M. Mutlu has received research support from the NIH and is Associate Editor of the ATS. S. Chiarella declares that he has no relevant conflicts of interest. ",

year = "2015",

month = jan,

day = "1",

doi = "10.1016/j.jaci.2014.09.037",

language = "English (US)",

volume = "135",

pages = "290--291",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

publisher = "Mosby Inc.",

number = "1",

}

TY - JOUR

T1 - β2-Agonist therapy may contribute to the air pollution and IL-6-associated risk of developing severe asthma with dual-positive TH2/TH17 cells

AU - Chiarella, Sergio E.

AU - Budinger, G. R.Scott

AU - Mutlu, Gökhan M.

N1 - Funding Information: Supported by National Institutes of Health grants R01 ES015024 (to G.M.M.) and R01 ES013995 (to G.R.S.B.). Funding Information: Disclosure of potential conflict of interest: G. R. S. Budinger has received research support from the National Institutes of Health (NIH) and is Deputy Editor of the American Thoracic Society (ATS). G. M. Mutlu has received research support from the NIH and is Associate Editor of the ATS. S. Chiarella declares that he has no relevant conflicts of interest.

PY - 2015/1/1

Y1 - 2015/1/1

UR - http://www.scopus.com/inward/record.url?scp=84920375827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920375827&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2014.09.037

DO - 10.1016/j.jaci.2014.09.037

M3 - Letter

C2 - 25445822

AN - SCOPUS:84920375827

SN - 0091-6749

VL - 135

SP - 290

EP - 291

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

IS - 1

ER -

β2-Agonist therapy may contribute to the air pollution and IL-6-associated risk of developing severe asthma with dual-positive TH2/TH17 cells

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this

β₂-Agonist therapy may contribute to the air pollution and IL-6-associated risk of developing severe asthma with dual-positive T_H2/T_H17 cells